Floatz logo

SPANLECORTEMLOCEL

Marginal Zone Lymphoma

Novartis PharmaceuticalsCell therapyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

106 Active assets in the Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

SPANLECORTEMLOCEL is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
61 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →